



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Reyataz®

**Common Name:** Atazanavir

**PDL Category:** Antiretrovirals – Protease Inhibitors

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Norvir®	Recommended

#### Summary

**Indications and Usage:** HIV-1 infection when used in combination with other antiretroviral agents

**Mechanism of Action:** Binds to active HIV protease sites and prevents processing of polyproteins in HIV-1 infected cells which prevents formation of mature virions

**Dosage Forms:** Capsules; 100mg, 150mg, 200mg, & 300mg

**Recommended Dosage:** Therapy naïve patients: 400mg once daily; Therapy-experienced patients: 300mg once daily plus ritonavir 100mg once daily

**Common Adverse Drug Reactions:** Rash, jaundice, scleral icterus, nausea

**Contraindications:** Previous hypersensitivity to any component of the product, concurrent use with drugs cleared by CYP3A.

**Manufacturer:** Bristol-Myers Squibb Co.

**Analysis:** Reyataz® is a new protease inhibitor that is intended to be used in combination with ritonavir in antiretroviral-experienced patients with prior virologic failure with other available products. At the time of the product's release, there were no good data regarding its use in therapy-naïve patients. In early clinical trials, the combination of Reyataz® & ritonavir was compared to lopinavir & ritonavir with the primary outcome measure being time-averaged difference in change from baseline in HIV RNA level. The Reyataz®/ritonavir reported a 1.58 log<sub>10</sub> copies/mL decrease from baseline compared to a 1.7 log<sub>10</sub> copies/mL decrease in the lopinavir/ritonavir combination. This study also showed a -7 cells/mm<sup>3</sup> difference in CD4+ change from baseline in favor of the Reyataz®/ritonavir group. The combination of Reyataz® and ritonavir has shown similar efficacy to lopinavir/ritonavir but decreases the pill burden to the patient (Reyataz® plus ritonavir typically results in a 3 pill/day regimen versus 4 pills/day with lopinavir/ritonavir). Due to Reyataz® not being a first line treatment option in therapy naïve patients, it is recommended to add Reyataz® to the Recommended Drug List as a Non-Recommended Drug.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input checked="" type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	